Correlation Between Sprint Bioscience and Stayble Therapeutics
Can any of the company-specific risk be diversified away by investing in both Sprint Bioscience and Stayble Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sprint Bioscience and Stayble Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sprint Bioscience AB and Stayble Therapeutics AB, you can compare the effects of market volatilities on Sprint Bioscience and Stayble Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sprint Bioscience with a short position of Stayble Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sprint Bioscience and Stayble Therapeutics.
Diversification Opportunities for Sprint Bioscience and Stayble Therapeutics
-0.41 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Sprint and Stayble is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Sprint Bioscience AB and Stayble Therapeutics AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stayble Therapeutics and Sprint Bioscience is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sprint Bioscience AB are associated (or correlated) with Stayble Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stayble Therapeutics has no effect on the direction of Sprint Bioscience i.e., Sprint Bioscience and Stayble Therapeutics go up and down completely randomly.
Pair Corralation between Sprint Bioscience and Stayble Therapeutics
Assuming the 90 days trading horizon Sprint Bioscience AB is expected to generate 0.82 times more return on investment than Stayble Therapeutics. However, Sprint Bioscience AB is 1.23 times less risky than Stayble Therapeutics. It trades about 0.12 of its potential returns per unit of risk. Stayble Therapeutics AB is currently generating about -0.02 per unit of risk. If you would invest 45.00 in Sprint Bioscience AB on May 14, 2025 and sell it today you would earn a total of 14.00 from holding Sprint Bioscience AB or generate 31.11% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Sprint Bioscience AB vs. Stayble Therapeutics AB
Performance |
Timeline |
Sprint Bioscience |
Stayble Therapeutics |
Sprint Bioscience and Stayble Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Sprint Bioscience and Stayble Therapeutics
The main advantage of trading using opposite Sprint Bioscience and Stayble Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sprint Bioscience position performs unexpectedly, Stayble Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stayble Therapeutics will offset losses from the drop in Stayble Therapeutics' long position.Sprint Bioscience vs. Cantargia AB | Sprint Bioscience vs. Saniona AB | Sprint Bioscience vs. Acarix AS | Sprint Bioscience vs. Gabather AB |
Stayble Therapeutics vs. Imugene Limited | Stayble Therapeutics vs. Lidds AB | Stayble Therapeutics vs. Sprint Bioscience AB |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |